{
  "docId": "019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "docSlug": "8f301a1a54ee099c965687c909e40052",
  "documentTitle": "Equillium | Investor Presentation Deck | 40 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 40,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes definition of SALT score in footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-cd1b-731e-ae5e-e1dc823ccd70/26",
  "deckHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "deckJsonHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70.json",
  "deckAnchorHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.3
      },
      "kind": "callout",
      "text": "Potential Target Product Profile: Safer alternative to JAKi with at least comparable efficacy. Patient-administered weekly/bi-weekly subcutaneous injection (similar to DUPIXENT™)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3049e905-becd-4ce7-ac0a-4663a315a991",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "diagram",
      "text": "Screening (5 weeks) -> Treatment (24 weeks, 2mg/kg IV bolus push) -> Follow-Up (4 weeks)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9398ea7-8467-4d47-b884-edfb740d437e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.3,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Study Objectives: Efficacy, Safety & tolerability, PK/PD and biomarkers",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d571e606-a410-4ba2-9139-dbcba0348f43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Population N=36: At least 35% scalp hair loss, as defined by a SALT score ≥35. Current episode of hair loss lasting >6 months to <7 years.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8f79177-d7a6-47f6-9fb7-a07012a34931",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.12,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "SALT = Severity of Alopecia Tool",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfaef67d-8d87-4b01-a128-31121a5f6a43",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 2 Study of EQ101 in Adults With Moderate to Severe AA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b11f295-c9fc-421f-a23e-aba15cae8013",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c3aa8671-d77d-405b-a6e1-e80a875cb4fd",
      "evidence": "The slide specifies the population for the phase 2 study (adults with moderate to severe AA), indicating a clear definition of the target audience.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}